Active	Status	Sponsor type	Region	Phase	Filter
1 Active 13 Inactive 14 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
eprenetapopt (APR-246) / Aprea
2019-002782-35: Study of systemic Azacitidine chemotherapy in combination with or without APR-246 in patients with a type of Myelodysplastic Syndrome	Not yet recruiting	3	154	Europe	APR-246, Concentrate for solution for infusion	Aprea Therapeutics AB, Aprea Therapeutics AB	Myelodysplastic Syndromes, Blood Cancer, Diseases [C] - Cancer [C04]